Search results
Showing 1 to 14 of 14 results for eribulin
Evidence-based recommendations on eribulin (Halaven) for treating locally advanced or metastatic (secondary) breast cancer in adults who have had only 1 course of chemotherapy.
View recommendations for TA515Show all sections
Evidence-based recommendations on eribulin (Halaven) for locally advanced or metastatic (secondary) breast cancer in adults who have had 2 or more courses of chemotherapy.
Evidence-based recommendations on sacituzumab govetican (Trodelvy) for treating unresectable, triple-negative locally advanced or metastatic breast cancer in adults after 2 or more systemic therapies, at least 1 of which was for advanced disease.
Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic breast cancer in adults after 2 or more anti-HER2 therapies.
Evidence-based recommendations on tucatinib (TUKYSA) for HER2-positive locally advanced or metastatic breast cancer in adults after 2 or more anti-HER2 treatment therapies.
Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for HER2-low metastatic or unresectable breast cancer after chemotherapy in adults.
Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations (TA952)
Evidence-based recommendations on talazoparib (Talzenna) for HER2-negative, locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations in adults.
TA006 Breast cancer - taxanes 14 June 2000 TA250 Breast cancer - eribulin 13 February 2012 TA350 Breast cancer (HER2 positive,...
TA006 Breast cancer - taxanes 14 June 2000 TA250 Breast cancer - eribulin 13 February 2012 TA350 Breast cancer (HER2 positive,...
Eribulin for the treatment of locally advanced or metastatic breast cancer (TA250)
This guidance has been updated and replaced by NICE technology appraisal guidance 423 and NICE technology appraisal guidance 515.
TA250/1 | Health-related quality of life studies comparing eribulin with vinorelbine and capecitabine should be conducted.
TA250/1 | Health-related quality of life studies comparing eribulin with vinorelbine and capecitabine should be conducted.
NICE provides access to new treatment option for advanced breast cancer
NICE has today (20 April 2021) published draft guidance recommending trastuzumab deruxtecan for use in the Cancer Drugs Fund (CDF).
Around 400 people with advanced breast cancer are set to benefit from a new treatment
Tucatinib works by blocking a specific area of the HER2 gene in cancer cells, which stops the cells from growing and spreading.